Table 3.
Association of serum asprosin with MetS and IR in fully adjusted models.
| Model adjustment | MetS | IR | ||||
|---|---|---|---|---|---|---|
| β | OR per 1 SD increase (95% CI) | P value | β | OR per 1 SD increase (95% CI) | P value | |
| Model 1 | 0.014 | 1.076 (1.047, 1.106) | <0.001 | 0.071 | 1.074 (1.046, 1.102) | <0.001 |
| Model 2 | 0.066 | 1.068 (1.039, 1.745) | <0.001 | 0.067 | 1.069 (1.042, 1.097) | <0.001 |
| Model 3 | 0.055 | 1.056 (1.022, 1.092) | 0.001 | 0.069 | 1.071 (1.042, 1.101) | <0.001 |
| Model 4 | 0.052 | 1.054 (1.019, 1.089) | 0.002 | 0.067 | 1.070 (1.041, 1.100) | <0.001 |
| Model 5 | 0.044 | 1.044 (1.009, 1.081) | 0.014 | |||
Model 1, adjusted for age and gender; Model 2, further adjusted for BMI; Model 3, further adjusted for lipid profiles (TC, TG, LDL-C, and HDL-C); Model 4, further adjusted for inflammatory markers (IL-6 and MCP-1); Model 5, further adjusted for HOMA-IR. IR, insulin resistance; BMI, body mass index; TC, total cholesterol; TG, triglycerides, LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; IL-6, interleukin-6; MCP-1, monocyte chemotactic protein-1. HOMA-IR, homeostasis model assessment of insulin resistance.